

Amendments to the Claims

I. Amendments

Please cancel claims 9-12, 14-17, 25-28, without prejudice or disclaimer, as directed to non-elected inventions.

II. The Claims of the Application

Claim 1. **(Previously amended)** A compound of the formula:



where R^1 is $\text{CH}_3\text{-(CH}_2\text{)}_n\text{-X-}$; in which

X is $\text{-C(O)-NH-CH}_2\text{-C(O)-}$, $\text{-NHCH}_2\text{-C(O)-}$, $\text{-ONH-CH}_2\text{-C(O)-}$,
 $\text{-OCH}_2\text{-CH}_2\text{-C(O)-}$, -CH=CH-C(O)- , -C(O)- , or a covalent bond;
and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP

AVVFVTRKNR QVCANPEKKW VREYINSLEMS

(SEQ ID No. 2) or a sequence which is a variant of said sequence,
the variant sequence having at least 40 % sequence homology with
said sequence;

or a pharmaceutically acceptable salt thereof.

Claim 2. **(Original)** The compound of claim 1, wherein n is 4 and
X is $\text{-C(O)-NH-CH}_2\text{-C(O)-}$.

Claim 3. **(Original)** The compound of claim 1, wherein n is 5
and X is $\text{-NH-CH}_2\text{-C(O)-}$.

Claim 4. **(Original)** The compound of claim 1, wherein n is 7 and X is -C(O)- .

- Claim 5. **(Original)** The compound of claim 1, wherein n is 8 and X is a covalent bond.
- Claim 6. **(Previously amended)** The compound of claim 1, wherein n is 4 and X is -ONH-CH₂-C(O)- .
- Claim 7. **(Previously amended)** The compound of claim 1, wherein n is 5 and X is -CH=CH-C(O)-.
- Claim 8. **(Original)** The compound of claim 1, wherein n is 4 and X is -OCH₂-CH₂-C(O)-.
- Claim 13. **(Previously amended)** A pharmaceutical composition for administration to a mammal having a disease state in that is alleviated by treatment with a RANTES inhibitor, which comprises a therapeutically effective amount of a compound of the formula:



where R¹ is CH₃-(CH₂)_n-X-; in which

X is -C(O)-NH-CH₂-C(O)-, -NHCH₂-C(O)-, -ONH-CH₂-C(O)-, -OCH₂-CH₂-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP
AVVFVTRKNR QVCANPEKKW VREYINSLEMS

(SEQ ID No. 2) or a sequence which is a variant of said sequence, the variant sequence having at least 40 % sequence homology with said sequence;

or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients.

- Claim 18. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 4 and X is $-\text{C}(\text{O})-\text{NH}-\text{CH}_2-\text{C}(\text{O})-$.
- Claim 19. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 5 and X is $-\text{NHCH}_2-\text{C}(\text{O})-$.
- Claim 20. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 7 and X is $-\text{C}(\text{O})-$.
- Claim 21 **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 8 and X is a covalent bond.
- Claim 22. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 4 and X is $-\text{ONH}-\text{CH}_2-\text{C}(\text{O})-$.
- Claim 23. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 5 and X is $-\text{CH}=\text{CH}-\text{C}(\text{O})-$.
- Claim 24. **(Previously added)** The pharmaceutical composition of claim 13, wherein N is 4 and X is $-\text{OCH}_2-\text{CH}_2-\text{C}(\text{O})-$.